Senores Q1 profit rises 56% on regulated markets growth
Revenue up 36% to ₹180.2 cr, EBITDA surges 87%. Results in line with guided trajectory.
— 5 earlier stories on Senores Pharmaceuticals Ltd. →What's new
- Q1 net profit up 56% to ₹31 cr on revenue of ₹180.2 cr.
- EBITDA surged 87% to ₹54 cr, margins up 800 bps.
- Regulated markets revenue grew 42%, driven by ANDA portfolio.
Why this matters
The 800 bps margin gain reflects the benefit of scale as the ANDA portfolio grows. At a trailing P/E of 51x, the stock already prices in strong growth; execution must sustain.
What we're watching
- Whether the margin gains hold as ANDA launches continue.
- Updates on USFDA inspections or pipeline milestones.
- Management commentary on full-year guidance.
The full read
Senores Pharmaceuticals delivered a strong Q1 FY27. Consolidated revenue rose 36% to ₹180.2 crore, and net profit climbed 56% to ₹31 crore. The standout: EBITDA surged 87% to ₹54 crore, lifting margins by 800 basis points — a sign that scale from its ANDA-driven regulated markets business is showing through. That segment grew 42%. The board also classified AVP Finance Anjali Shah as senior management, a routine move. The numbers are in line with the trajectory management already laid out. At a trailing P/E of 51x, the market is paying for delivery. This quarter delivers. The next test is whether the margin gains hold as the pipeline grows.
Questions answered
- What drove Senores' strong Q1 performance?
- The regulated markets business led with a 42% revenue jump, fueled by an expanded ANDA portfolio. EBITDA margins improved 800 bps, suggesting scale benefits.
- Is this growth sustainable at current margins?
- The 800 bps margin improvement suggests scale benefits, but sustainability depends on ANDA filings and pricing in regulated markets. No full-year guidance was given.
- How does the valuation look after this quarter?
- Senores trades at a trailing P/E of about 51x, reflecting high growth expectations. Q1 results are in line with management's indicated path, so the valuation likely already factors this in.
- What is the significance of Anjali Shah's appointment as senior management?
- Ms. Shah was already AVP Finance; the reclassification is a routine internal designation change and adds no new investment relevance.
- How does this quarter compare to Senores' trailing growth?
- Q1 revenue growth of 36% is lower than the trailing screener figure of 53.4% (different period), but profit growth of 56% is broadly in line with trailing PAT growth of 104.1%.
Story so far
All notes on SENORES →- 27 Jul 2026 · 3:42 PM IST Senores Q1 profit rises 56% on regulated markets growth
- today Senores Pharma targets 50-60% PAT growth after Q1 beat
- today Senores delays Atlanta plant, redirects ₹65 cr of IPO funds
- today Senores Q1 revenue jumps 36% to ₹180 cr, profit up 56%
- today Senores' Q1: Revenue up 36%, profit up 56% — in line with guidance